StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.23−0.46 (-5.29%)

Close on Nov 18, 2026Market cap $239.70MP/E –Yield –

Enanta Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Enanta Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $63.00M, down 3.6% year over year. For fiscal 2026 it was $63.00M, down 3.6% from the year before. Over ten years it grew -3.3% a year on average. The highest annual figure on record is $206.63M in fiscal 2018.

Annual revenue

PeriodPeriod endValueChange
FY2026Sep 30, 2026$63.00M-3.6%
FY2025Sep 30, 2025$65.32M-3.4%
FY2024Sep 30, 2024$67.64M-14.6%
FY2023Sep 30, 2023$79.20M-8.1%
FY2022Sep 30, 2022$86.16M-11.2%
FY2021Sep 30, 2021$97.07M-20.7%
FY2020Sep 30, 2020$122.47M-40.3%
FY2019Sep 30, 2019$205.20M-0.7%
FY2018Sep 30, 2018$206.63M+101.0%
FY2017Sep 30, 2017$102.81M+16.5%
FY2016Sep 30, 2016$88.27M-45.1%
FY2015Sep 30, 2015$160.88M+237.0%
FY2014Sep 30, 2014$47.74M+48.9%
FY2013Sep 30, 2013$32.05M-23.1%
FY2012Sep 30, 2012$41.71M-0.4%
FY2011Sep 30, 2011$41.88M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ3 2026Sep 30, 2026$12.87M-14.9%
Q3 FY2026CQ2 2026Jun 30, 2026$14.36M-15.3%
Q2 FY2026CQ1 2026Mar 31, 2026$17.16M+17.5%
Q1 FY2026CQ4 2025Dec 31, 2025$18.62M+3.6%
Q4 FY2025CQ3 2025Sep 30, 2025$15.13M-11.3%
Q1 FY2025CQ4 2024Dec 31, 2024$16.96M-5.8%
Q4 FY2024CQ3 2024Sep 30, 2024$14.61M-22.8%
Q3 FY2024CQ2 2024Jun 30, 2024$17.97M-4.9%
Q2 FY2024CQ1 2024Mar 31, 2024$17.05M-4.2%
Q1 FY2024CQ4 2023Dec 31, 2023$18.00M-23.7%
Q4 FY2023CQ3 2023Sep 30, 2023$18.93M-6.8%
Q3 FY2023CQ2 2023Jun 30, 2023$18.89M-3.0%
Q2 FY2023CQ1 2023Mar 31, 2023$17.80M-4.9%
Q1 FY2023CQ4 2022Dec 31, 2022$23.59M-14.7%
Q4 FY2022CQ3 2022Sep 30, 2022$20.32M-13.8%
Q3 FY2022CQ2 2022Jun 30, 2022$19.48M-9.9%
Q2 FY2022CQ1 2022Mar 31, 2022$18.72M-7.0%
Q1 FY2022CQ4 2021Dec 31, 2021$27.65M-12.9%
Q4 FY2021CQ3 2021Sep 30, 2021$23.58M-0.2%
Q3 FY2021CQ2 2021Jun 30, 2021$21.62M+15.9%
Q2 FY2021CQ1 2021Mar 31, 2021$20.13M-27.1%
Q1 FY2021CQ4 2020Dec 31, 2020$31.74M-39.6%
Q4 FY2020CQ3 2020Sep 30, 2020$23.63M-53.9%
Q3 FY2020CQ2 2020Jun 30, 2020$18.65M-58.0%
Q2 FY2020CQ1 2020Mar 31, 2020$27.62M-30.3%
Q1 FY2020CQ4 2019Dec 31, 2019$52.57M-24.8%
Q4 FY2019CQ3 2019Sep 30, 2019$51.31M-23.6%
Q3 FY2019CQ2 2019Jun 30, 2019$44.37M-22.5%
Q2 FY2019CQ1 2019Mar 31, 2019$39.63M-10.0%
Q1 FY2019CQ4 2018Dec 31, 2018$69.89M+83.4%
Q4 FY2018CQ3 2018Sep 30, 2018$67.21M-11.5%
Q3 FY2018CQ2 2018Jun 30, 2018$57.26M+662.4%
Q2 FY2018CQ1 2018Mar 31, 2018$44.05M+391.7%
Q1 FY2018CQ4 2017Dec 31, 2017$38.11M+265.8%
Q4 FY2017CQ3 2017Sep 30, 2017$75.93M+491.3%
Q3 FY2017CQ2 2017Jun 30, 2017$7.51M–
Q2 FY2017CQ1 2017Mar 31, 2017$8.96M–
Q1 FY2017CQ4 2016Dec 31, 2016$10.42M–
Q4 FY2016CQ3 2016Sep 30, 2016$12.84M–

More Enanta Pharmaceuticals figures

See a number that looks wrong?